<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979611</url>
  </required_header>
  <id_info>
    <org_study_id>FirstAHFujian11</org_study_id>
    <nct_id>NCT04979611</nct_id>
  </id_info>
  <brief_title>The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma</brief_title>
  <official_title>The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4&#xD;
      positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the&#xD;
      patient diagnosed with endogenous hyperinsulinemic hypoglycaemia. And the diagnostic value&#xD;
      will be performed. A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be&#xD;
      injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT&#xD;
      images.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The glucagon-like peptide-1 receptor (GLP-1R) is an emerging target due to its high&#xD;
      expression in benign insulinomas. 68Ga-NOTA-exendin-4 is an optimal probe targeting GLP-1R.&#xD;
      The clinical use of 68Ga-NOTA-exendin-4 PET/CT in detecting insulinomas will be evaluated.&#xD;
      And the comparation between PET diagnostic value and CT / MRI will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard uptake value (SUV)</measure>
    <time_frame>From right after tracer injection to 1-hours post-injection</time_frame>
    <description>Determination of SUV for detected lesions and discernible organs of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE Standard uptake value (SUV) of the lesion will be recorded</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Insulinoma</condition>
  <arm_group>
    <arm_group_label>Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously. PET/CT imaging will be performed at 30-60 min post-injection.Visual and semiquantitative method will be used to assess the PET/CT images.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-NOTA-exendin-4</intervention_name>
    <description>A single dose of 37-111 Mega-Becquerel (MBq) 68Ga-NOTA-exendin-4 will be injected intravenously</description>
    <arm_group_label>Patients will undergo 68Ga-NOTA-exendin-4 PET/CT imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.age â‰¥6 years old 2.Patients with hypoglycaemia 3.Endogenous hyperinsulinemic&#xD;
             hypoglycaemia 4.Enhanced CT or MRI within 1 month 5.Signed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Breast feeding 2.Pregnancy or the wish to become pregnant within 6 months 3.Renal&#xD;
             function: serum creatinine during 41-73umol/L 4.Any medical condition may&#xD;
             significantly interfere with study compliance; 5.Known allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>weibing miao, MD</last_name>
    <phone>86-0591-87981618</phone>
    <email>miaoweibing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shaobo yao, MD</last_name>
    <phone>86-0591-87981618</phone>
    <email>yaoshaobo008@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Miao, MD</last_name>
      <phone>059187981618</phone>
      <email>miaoweibing@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaobo Yao, MD</last_name>
      <phone>059187981619</phone>
      <email>yaoshaobo008@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Weibing Miao, PhD</investigator_full_name>
    <investigator_title>Director of Nuclear Medicine Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

